These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34660712)

  • 1. Folic Acid Attenuates Contrast-Induced Nephropathy in Patients With Hyperhomocysteinemia Undergoing Coronary Catheterization: A Randomized Controlled Trial.
    Peng L; Shui X; Tan F; Li Z; Ling Y; Wu B; Chen L; Li S; Peng H
    Front Cardiovasc Med; 2021; 8():707328. PubMed ID: 34660712
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remote ischemic preconditioning reduces the incidence of contrast-induced nephropathy in patients undergoing coronary angiography/intervention: Systematic review and meta-analysis of randomized controlled trials.
    Pranata R; Tondas AE; Vania R; Toruan MPL; Lukito AA; Siswanto BB
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1200-1212. PubMed ID: 31912996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.
    Chen F; Liu F; Lu J; Yang X; Xiao B; Jin Y; Zhang J
    Eur J Med Res; 2018 May; 23(1):23. PubMed ID: 29776437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
    Fu N; Yang S; Zhang J; Zhang P; Liang M; Cong H; Lin W; Tian F; Lu C
    Int Urol Nephrol; 2018 Jan; 50(1):105-112. PubMed ID: 29071556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of plasma homocysteinemia on contrast-induced nephropathy after percutaneous coronary intervention in patients with coronary syndrome].
    Yan G; Kong W; Wang D; Qiao Y; Sha X; Cheng T; Zhang H; Hou J; Tang C; Ma G
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Jan; 44(1):32-7. PubMed ID: 26813550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
    Kim SJ; Choi D; Ko YG; Kim JS; Han SH; Kim BK; Kang SW; Hong MK; Jang Y; Choi KH; Yoo TH
    Am J Cardiol; 2011 Oct; 108(8):1086-91. PubMed ID: 21791335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
    Shehata M; Hamza M
    Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the risk factors for contrast-induced nephropathy in over-aged patients receiving coronary intervention.
    Pan HC; Wu XH; Wan QL; Liu And BH; Wu XS
    Exp Biol Med (Maywood); 2018 Aug; 243(12):970-975. PubMed ID: 30299175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale.
    Mujtaba A; Taher MA; Hazza MA; Al-Rubaye HM; Kata AH; AbdulWahab H; AbdulBari A; AlRubay HK
    Cardiol Ther; 2018 Jun; 7(1):101-106. PubMed ID: 29785539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
    Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
    Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
    J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of probucol on preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention].
    Suo XQ; Yang SC; Ma ZH; Sun TT; Zhang WY; Cong HL; Lin WH; Lu CZ; Tian FS; Fu NK
    Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(41):3234-3238. PubMed ID: 29141361
    [No Abstract]   [Full Text] [Related]  

  • 20. Preventive effect and mechanism of compound Danshen dripping pills on contrast-induced nephropathy after percutaneous coronary interventional.
    Fu H; Wang L; Ying S; Zhao Z; Zhang P
    Front Cardiovasc Med; 2023; 10():1211982. PubMed ID: 38124888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.